Back to top
more

Galapagos (GLPG)

(Delayed Data from NSDQ)

$27.27 USD

27.27
95,711

-0.38 (-1.37%)

Updated May 24, 2024 03:59 PM ET

After-Market: $27.27 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Vertex Completes Enrollment in Triple Combination Studies

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) completes enrollment in two phase III studies evaluating VX-659 triple combination regimen in CF patients. Data is expected in the fourth quarter of 2018.

    Gilead, Galapagos Spondylitis Drug Meets Primary Endpoint

    by Zacks Equity Research

    Gilead's (GILD) ankylosing spondylitis candidate, filgotinib meets primary endpoint in phase II study.

      Vertex Inks Reimbursement Agreement for Orkambi in Australia

      by Zacks Equity Research

      Vertex Pharmaceuticals (VRTX) finalizes a reimbursement agreement with Australian government, which will improve the access to the drug.

        Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q2

        by Zacks Equity Research

        The FDA accepts Catalyst's (CPRX) NDA for its lead pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and an action date of Nov 28, 2018 is set for the same.

          Arena Pharmaceuticals (ARNA) Q2 Loss Wider Than Expected

          by Zacks Equity Research

          Arena Pharmaceuticals (ARNA) misses second-quarter earnings estimates. Its three key pipeline candidates, ralinepag, etrasimod and Olorinab/APD371, remain in focus.

            Can the Rally in Galapagos (GLPG) Shares Continue?

            by Zacks Equity Research

            Galapagos NV (GLPG) has been on the move lately as the stock has risen by 23.4% in the past four weeks, and it is currently trading well above its 20-Day SMA

              Galapagos (GLPG): Moving Average Crossover Alert

              by Zacks Equity Research

              Galapagos NV (GLPG) is looking like an interesting pick from a technical perspective

                Vertex's Shares Rally as a Rival's CF Candidate Disappoints

                by Zacks Equity Research

                Vertex Pharmaceuticals' (VRTX) stock rallies on disappointing study results on rival Galapagos' cystic fibrosis candidate. Vertex's third CF drug receives approval in Canada.

                  Gilead & Galapagos Announce Positive Data on Filgotinib

                  by Zacks Equity Research

                  Gilead (GILD) and partner Galapagaos (GLPG) announces positive data on filgotinib for the treatment of psoriatic arthritis in adults and ulcerative colitis.

                    New Strong Sell Stocks for February 16th

                    by Zacks Equity Research

                    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                      Lilly's Taltz Positive in Phase III Label Expansion Study

                      by Zacks Equity Research

                      Lilly's (LLY) psoriasis drug, Taltz, meets all endpoints in a phase III study evaluating it in patients with ankylosing spondylitis.

                        New Strong Sell Stocks for February 7th

                        by Zacks Equity Research

                        Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

                          New Strong Sell Stocks for February 7th

                          by Zacks Equity Research

                          Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                            Galapagos Reports Topline Data From Osteoarthritis Study

                            by Zacks Equity Research

                            Galapagos' (GLPG) osteoarthritis candidate, GLPG1972, reduces level of ARGS neoepitope, a cartilage breakdown biomarker, by more than half in an early stage study.

                              Galapagos' CF Candidate Shows Potential in Phase II Study

                              by Zacks Equity Research

                              Galapagos' (GLPG) CFTR corrector candidate, GLPG2222, shows potential in a phase II study on CF patients.

                                Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises 2017 View

                                by Zacks Equity Research

                                Vertex Pharma (VRTX) third-quarter earnings increased from the year-ago period led by strong sales of CF drugs.

                                  Is a Surprise Coming for Galapagos (GLPG) This Earnings Season?

                                  by Zacks Equity Research

                                  Galapagos (GLPG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                    Quanta Services (PWR) Q2 Earnings: What's in the Cards?

                                    by Zacks Equity Research

                                    Quanta Services' (PWR) second-quarter 2017 earnings results will likely benefit from thriving engineering and project management services, but concerns like regulatory delays remain.

                                      GoPro (GPRO) to Report Q2 Earnings: A Beat in Store?

                                      by Zacks Equity Research

                                      GoPro's (GPRO) second-quarter 2017 results should benefit from strong market traction of HERO5 cameras and restructuring measures, but risks of declining revenues and stiff competition remain.

                                        Match Group (MTCH) to Report Q2 Earnings: What's in Store?

                                        by Zacks Equity Research

                                        Match Group's (MTCH) second-quarter 2017 earnings results should benefit from steady market traction and brand visibility, but concerns like currency volatility remain.

                                          Vertex (VRTX) Q2 Earnings Top on Solid Cystic Fibrosis Sales

                                          by Zacks Equity Research

                                          Vertex Pharmaceuticals Incorporated's (VRTX) Q2 results were encouraging, as it topped earnings and revenues expectations backed by higher sales of both its CF drugs.

                                            Will Flowserve (FLS) Pull Off a Surprise in Q2 Earnings?

                                            by Zacks Equity Research

                                            We expect second-quarter results of Flowserve (FLS) to gain traction from its strong operation model, solid productivity and geographical diversity.

                                              Galapagos (GLPG) Looks Good: Stock Adds 6.2% in Session

                                              by Zacks Equity Research

                                              Galapagos (GLPG) was a big mover last session, as the company saw its shares rise over 6% on the day.

                                                Galapagos-Gilead Begin Phase II Study on Uveitis Candidate

                                                by Zacks Equity Research

                                                Galapagos NV (GLPG) has announced initiation of a new phase II study, evaluating its lead pipeline candidate filgotinib for treatment of adult patients with non-infectious uveitis.

                                                  Illumina (ILMN) Launches VeriSeq NIPT Solution in Europe

                                                  by Zacks Equity Research

                                                  Illumina, Inc. (ILMN) recently announced the launch of a solution pertaining to its noninvasive prenatal testing (NIPT) range in Europe.